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A HERBAL REMEDY DERIVED FROM SUBSPECIES OF ROSA CANINA,
IMPROVES THE IMMUNE RESPONSE, WORKING CAPACITY AND
WELL-BEING OF DOGS? A PARALLEL, PLACEBO-CONTROLLED,
DOUBLE-BLIND, RANDOMIZED STUDY
K. Winther1, A. Ragone1, A.V. Hansen1, P. Hansen1, A. Kharazmi2
1Dept. of Clinical Biochemisty, Frederiksberg Hosp., Univ. of Copenhagen,
Frederiksberg, Denmark; 2Dept. of Microbiol., RigsHosp.et, Univ. of
Copenhagen, Copenhagen, Denmark
Purpose: LitoVet a standardised powder made from subspecies of rose-hip
(rosa-canina), produced by Hyben-Vital, Langeland, Denmark, has shown
anti-inﬂammatory properties and improves the ﬂexibility of joints and
well-being in humans with osteoarthritis as well as in racing horse. It
has also been demonstrated that the present powder improves the quality
of human cartilage cells. The present study aimed to test whether the
same powder might improve the immune response, working capacity and
well-being of dogs.
Methods: Eighty six Greyhound dogs represented by both sexes mean
age 4.25±1.75 years and weight 30.95±4.0 kg were randomly allocated to
either LitoVet or placebo treatment for a three-month period. The animals
were randomized in blocks of three with two dogs given LitoVet 10 gram
daily as a dry powder added to the food and one dog given the same
amount of placebo powder with a similar taste, odour and colour. Both
groups were then treated for a three-month period.
The anti-inﬂammatory capacity was estimated as chemotaxis of periph-
eral blood neutrophil leucocytes using a Boyden chamber and opsonized
zymosan as a trigger and by estimating the total leukocyte counts. Anti-
oxidative capacity was estimated by using chemiluminescence. Working
capacity, endurance, motivation for different activities including training,
litheness, speed, mood and quality of the fur was evaluated by the staff
training the dogs by using standardised questionnaires after 6 and 12
weeks, respectively. In addition speed was estimated as meter/second
in hounds during competition. LitoVet and placebo treated dogs were
compared using Mann-Whitney. A p value of 0.050 or less was regarded as
statistically signiﬁcant.
Results: In vitro studies on neutrophils indicated a dose-dependent
anti-inﬂammatory and anti-oxidative capacity of LitoVet (p<0.048). Anti-
inﬂammatory and anti-oxidative properties were also detected in vivo
when the dogs had been treated for twelve weeks with LitoVet (p<0.046
and p <0.010, respectively). The questionnaires developed a consistent
pattern. After 6 weeks treatment only litheness showed signiﬁcant im-
provement in favour of active treatment (p<0.017). After 12 weeks of
treatment a signiﬁcant change in favour of LitoVet treatment as com-
pared to placebo was seen in the following parameters: working capacity
p<0.021, endurance p< 0.047, motivation for different activities including
training p<0.014, litheness 0.002, speed p< 0.027, mood p< 0.026 and
quality of the fur p<0.045. The improvement observed in the question-
naires was supported by the estimation of speed in competing dogs. There
was no signiﬁcant change in appetite or weight.
Conclusions: The present data suggest that LitoVet exhibits anti-inﬂamma-
tory properties in dogs and works as a strong antioxidant. This can explain
why the actively treated group of dogs showed an improvement in so many
different activities as working capacity, litheness, speed and quality of the
fur.
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HEALTH STATUS OF PATIENTS WHO RECEIVED TAPENTADOL PROLONGED
RELEASE DURING AN OPEN-LABEL EXTENSION STUDY
B. Kuperwasser1, E. McCann1, I. Van Hove2, R. Lange3, T. Häufel4,
M. Etropolski1
1Johnson & Johnson Pharmaceutical Res. & Dev. (PRD), L.L.C., Raritan, NJ;
2Johnson & Johnson PRD, Div. of Janssen Pharmaceutica, N.V., Beerse, Belgium;
3Global Dev., Grünenthal GmbH, Aachen, Germany; 4Global Drug Safety,
Grünenthal GmbH, Aachen, Germany
Purpose: Health status was assessed using the EuroQol-5 Dimension (EQ-
5D) questionnaire in a 1-year open-label extension study of tapentadol
prolonged release for the management of moderate to severe chronic pain
(ClinicalTrials.gov Identiﬁer: NCT00487435).
Methods: Patients were eligible for enrollment in this study if they com-
pleted 1 of 4 phase 3 studies (2 studies that evaluated the eﬃcacy of
tapentadol prolonged release and oxycodone controlled release compared
with placebo in patients with osteoarthritis pain [NCT00421928] or low
back pain [NCT00449176], a crossover study that evaluated dose conversion
between tapentadol immediate release and tapentadol prolonged release
in patients with low back pain [NCT00594516], or a 1-year study that
evaluated the long-term safety of tapentadol prolonged release compared
with oxycodone controlled release in patients with osteoarthritis or low
back pain [NCT00361504]). Patients who completed either of the eﬃcacy
studies, the crossover study, or who received oxycodone controlled release
in the 1-year safety study were titrated to their optimal therapeutic dose
of tapentadol prolonged release (100-250 mg bid) during a titration period
of up to 4 weeks, and all patients continued on their optimal dose during
a maintenance period of up to 48 weeks. Patients who received tapentadol
prolonged release in the 1-year safety study continued on their optimal
dose determined during that study. Average pain intensity during the past
24 hours was recorded every 4 weeks during the maintenance phase; mean
pain intensity at endpoint was calculated using the last observation carried
forward for values missing after early discontinuation. The EQ-5D mea-
sures health status using 5 dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression [3 possible levels: no problems,
some problems, or extreme problems], as well as a health status index;
patients completed an EQ-5D questionnaire at the end of treatment as well
as at Months 1, 2, 3, 6, 9, and 12. Treatment-emergent adverse events
(TEAEs) were recorded throughout the study.
Results: Patients (N = 1154) reported mean pain intensity scores of 3.87
at baseline and 3.65 at endpoint. At endpoint, the percentages of patients
(regardless of prior treatment) who reported the most positive response
on each dimension were as follows: no problems with mobility, 43.9%; no
problems in self-care, 82.9%; no problems with performing usual activities,
40.6%; no pain or discomfort, 17.2%; and no anxiety or depression, 71.7%.
Mean (standard error) changes from baseline on each dimension were as
follows: mobility, -0.0 (0.01); self-care, -0.0 (0.01); usual activities, -0.0
(0.02); pain or discomfort, -0.1 (0.02); and anxiety or depression, -0.0
(0.01). The mean (SE) change from baseline in health status index was 0.0
(0.01). The most common (≥10%) TEAEs reported during the study were
headache (13.1%), nausea (11.8%), and constipation (11.1%).
Conclusions: The eﬃcacy of tapentadol prolonged release for the manage-
ment of moderate to severe chronic pain and improvements in health status
with tapentadol prolonged release treatment have been demonstrated and
reported previously in phase 3 studies. Treatment with tapentadol pro-
longed release (100-250 mg bid) for up to 1 year in this open-label
extension study maintained pain control and health status for patients with
moderate to severe osteoarthritis or low back pain. These results support
the long-term use of tapentadol prolonged release for the management of
moderate to severe chronic pain.
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SCREENING, RECRUITMENT AND BASELINE CHARACTERISTICS OF THE
LONG-TERM EVALUATION OF GLUCOSAMINE SULPHATE (LEGS) STUDY
PARTICIPANTS
M. Fransen1, M. Agaliotis1, L. Nairn1, M. Votrubec1, L. Bridgett1,
M. Woodward2
1Univ. of Sydney, Lidcombe, Australia; 2The George Inst. for Intl. Hlth., Sydney,
Australia
Purpose: Clinical trials evaluating potential ’disease-modifying’ agents for
osteoarthritis are required to demonstrate both symptomatic and structural
beneﬁt. Ideally, to reduce ceiling or ﬂoor effects, study participants are
required to have at least moderate pain, yet retain suﬃcient tibiofemoral
joint space to allow the measurement of narrowing over time. To describe
study recruitment procedures and baseline demographics of people with
symptomatic knee osteoarthritis participating in the Long-term Evaluation
of Glucosamine Sulphate (LEGS) study (NCT00513422).
Methods: The LEGS study is a 2×2 factorial design randomised placebo-
controlled clinical trial allocating participants to glucosamine sulphate
(1500mg) and chondroitin sulphate (800mg) or matching placebo for two
years. Participants are required to attend annual clinic assessments (includ-
ing radiographs, knee MRI) and complete a bimonthly 7-day Participant
Diary collecting prospective data on pain, physical activity, analgesia and
work disability. Participants were recruited by small advertisements in
local and national newspapers or directly from general practice. The LEGS
study utilized a three stage screening process:
1. Telephone screening,
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2. X-ray screening, and
3. Two week run-in period
Telephone screening was comprehensive and included questions on age,
seafood allergies, co-morbidities (RA, bilateral knee replacements, unstable
diabetes, recent lower limb surgery or intra-articular injections), intention
to undergo joint replacement in next year, opioid use, informed that knee
is ‘bone-on-bone’, willingness to be randomised, willingness to adhere to
study procedures and level of knee pain ‘at its worst’ in the past week.
The subsequent radiographic screening required evidence of predominant
medial tibio-femoral joint disease but retaining at least 2 mm of medial
joint space width in a suﬃciently symptomatic (≥4 out of 10) knee. If still
eligible, a two week ‘run-in’ period required adherence to study treatment
capsules and return of a completed Participant Diary.
Results: From an initial 2,682 telephone enquiries, 605 people were
randomised (October 2007-2009). The main barrier to recruitment was
unwillingness to be randomised to placebo (Figure 1).
Figure 1. Recruitment ﬂowchart.
Fifty percent of the radiographic ineligibility was due to complete loss of
medial tibio-femoral joint space. A further 13% withdrew from participation
during the ‘run-in’ period. The baseline demographics of the LEGS study
cohort (Table1) demonstrate the required screening pain of ≥4 out of 10
was not maintained at the subsequent baseline assessment (WOMAC) or
7-day Participant Diary by many participant.
Table 1. Baseline demographics
N=605 n, % Pain and disability Mean (sd)
Age mean (sd) 60.3 (8.2) WOMAC pain (0-100) 33.2 (17.6)
BMI mean (sd) 28.9 (5.8) WOMAC function (0-100) 32.4 (18.2)
Female 339, 56% SF-12 PCS 41.3 (9.5)
Obese 214, 35% SF-12 MCS 52.8 (10.0)
No comorbidity 73, 12% Mean pain over 7-days (0-10) 3.5 (1.8)
High blood pressure 195, 32% Max pain over 7-days (0-10) 4.6 (2.1)
Back pain 138, 23%
Stomach problems 67, 11%
Depression 62, 10%
Heart Disease 55, 9%
Diabetes 35, 6%
Paracetamol for knee pain 211, 35%
NSAIDs for knee pain 119, 20%
Conclusions: A comprehensive telephone screening reduced the burden
of radiographic screenings. The two week ’run- in’ of study procedures
further reduced the number of participants likely to drop out soon after
randomisation. It is diﬃcult to identify people with knee osteoarthritis that
have at least moderate ongoing pain, yet retain medial tibio-femoral joint
space width >2mm.
339
NOVEL LIPOSOMAL GEL OF AN ANTI-INFLAMMATORY AGENT:
RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL FOR EVALUATION OF THE
EFFICACY AND SAFETY IN PATIENTS WITH SIGNS AND SYMPTOMS OF
OSTEOARTHRITIS OF THE KNEES
V. Goni1, A. Bhatia2, S. Pebam1, A. Taneja1, N. Tahasildar1, S. Rajan1,
B. Amarji2, B. Singh2, O.P. Katare2
1Post Graduate Inst. of Med. Ed. and Res., Chandigarh, India; 2Univ. Inst. of
Pharmaceutical Sci., Panjab Univ., Chandigarh, India
Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are the “Gold
Standards” in the treatments of various pain and inﬂammation related dis-
orders like arthritis. However, their oral administration and use of newer
selective COX-2 NSAIDs known to induce severe intolerance in patients.
Thus, the present work aims to compare the eﬃcacy and safety of a
epicutaneously applied diclofenac in novel liposomal gel vis-à-vis marketed
gel and placebo for relief of signs and symptoms in osteoarthritis (OA) of
knee.
Methods: This was a randomized, double-blind, controlled trial on 36 pa-
tients with knee osteoarthritis. They were randomly assigned to liposomal
gel, marketed gel and placebo, twice a day for 6 weeks. The patients
were assessed by primary eﬃcacy outcome measures included the changes
from baseline to end of study on the WOMAC (Western Ontario McMaster
Universities) Osteoarthritis Index. The radiographic imaging of OA in the
knee was also performed for Kellgren-Lawrence criteria. Safety of the gel
was also assessed by evaluating adverse events, vital signs, and irritation at
the application site.
Results: In liposomal gel treated group, the pain, stiffness and diﬃculty
performing routine activities showed statistically signiﬁcantly improve-
ments on 6 weeks of treatment compared to the other tested gels. While,
all the treatments were found to be well tolerated with no observed
adverse event.
Conclusions: Diclofenac in liposomal gel is superior to other tested formu-
lations viz. marketed gel and placebo in the relieving the symptoms of OA
of the knee. Hence, it can be concluded that diclofenac in liposomal gel can
be a rational alternative to oral diclofenac formulations for management of
various pain and inﬂammation related ailments including osteoarthritis.
Epidemiology & Health Services Research
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OSTEOARTHRITIS DUE TO SURGERY FOR KNEE INJURY IN YOUNGER
ADULTS
E. Badley, M. Canizares, A. Davis
Univ. Hlth.Networks, Toronto, ON, Canada
Purpose: The literature suggests ACL injuries and meniscal lesions are
associated with the development of knee osteoarthritis (OA). There is
limited evidence that surgical repair of these lesions diminishes future
development of knee OA. A review of the long-term consequences of these
injuries suggests that some 50% of those undergoing meniscectomy will
develop OA between10 to 20 years after the surgery. Estimates from the
literature indicate that 10% to 90% of individuals with ACL injury develop
OA within 10 to 20 years of the lesion. This raises the question as to
what proportion of all knee OA cases might be associated with previous
arthroscopic surgery.
Methods: A study to estimate the proportion of individuals who will
develop OA after having arthroscopic surgery was designed by juxtaposing
data form different sources. (a) Data on the age- and sex-speciﬁc rates of
arthroscopic surgery (closed repair of the knee which includes menisec-
tomy and ACL repairs) in Ontario, Canada for the population aged 5-45
years, (b) data on the age and sex incidence of OA estimated from physician
billing data in British Columbia, Canada, (c) Population data for Canada,
and d) estimates of the proportion of individuals with arthroscopic surgery
who develop OA were combined to calculate estimates of the number of
incident OA cases likely due to arthroscopic surgery at the end of a 10 year
period. The rates of arthroscopic surgery were applied to the population to
estimate the number of individuals with this type of surgery. OA incidence
rates were also applied to the population to estimate the number of new
OA cases every year. The following scenarios for the proportion developing
OA over a period of 10 years were used: 10%, 20%, 30% and 40%. The main
assumptions made were: constant arthroscopic rates and incidence rates of
